|
|
|
|||||||
|
|||||||||
J Biol Chem, Vol. 273, Issue 39, 25472-25479, September 25, 1998
From the Cancer Genetics Laboratory, Department of Biochemistry,
University of Otago, Dunedin, New Zealand
PAX2, a member of the PAX
gene family of developmental transcription factors, is expressed at
high levels in the developing eyes, ears, central nervous and
urogenital systems, as well as in Wilms' tumor and renal cell
carcinoma. Expression of PAX2 in the urogenital system is
associated with proliferating cells of the ureteric bud and the
differentiating nephrogenic mesenchyme. To date, little is known about
the molecular mechanisms controlling the regulation of PAX2
expression. This report describes the cloning and characterization of
the human PAX2 gene promoter and localization of the
transcription start sites in fetal kidney and Wilms' tumor. We
identified two transcription start sites in a Wilms' tumor sample,
which were found to be different from that in fetal kidney. The
activity of a deletion series of the PAX2 promoter was
assessed in NIH-3T3, COS-7, 293, and Madin-Darby canine kidney cells.
Although some differences were observed in the activity of each
promoter construct, the profile of activity for the promoter fragment
series was similar in each experiment, regardless of cell type. The WT1 tumor suppressor protein, which has previously been shown to repress murine Pax2 expression in vitro, was shown to
also repress expression from the human PAX2 promoter.
Cloning and Characterization of the Human PAX2
Promoter
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  V.-D. Luu, G. Boysen, K. Struckmann, S. Casagrande, A. von Teichman, P. J. Wild, T. Sulser, P. Schraml, and H. Moch Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., May 15, 2009; 15(10): 3297 - 3304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B Silberstein, K. Van Horn, E. Hrabeta-Robinson, and J. Compton Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system. J. Endocrinol., August 1, 2006; 190(2): 225 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Torban, A. Dziarmaga, D. Iglesias, L. L. Chu, T. Vassilieva, M. Little, M. Eccles, M. Discenza, J. Pelletier, and P. Goodyer PAX2 Activates WNT4 Expression during Mammalian Kidney Development J. Biol. Chem., May 5, 2006; 281(18): 12705 - 12712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. Zhang, B. Moini, and J. R. Ingelfinger Angiotensin II Increases Pax-2 Expression in Fetal Kidney Cells Via the AT2 Receptor J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1452 - 1465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dziarmaga, P. Clark, C. Stayner, J. P. Julien, E. Torban, P. Goodyer, and M. Eccles Ureteric Bud Apoptosis and Renal Hypoplasia in Transgenic PAX2-Bax Fetal Mice Mimics the Renal-Coloboma Syndrome J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2767 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maeshima, K. Maeshima, Y. Nojima, and I. Kojima Involvement of Pax-2 in the Action of Activin A on Tubular Cell Regeneration J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2850 - 2859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ma, D. Li, L. Chai, A. M. Luciani, D. Ford, J. Morgan, and A. L. Maizel Cloning and Characterization of Two Promoters for the Human HSAL2 Gene and Their Transcriptional Repression by the Wilms Tumor Suppressor Gene Product J. Biol. Chem., December 14, 2001; 276(51): 48223 - 48230. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |